Duodenitis and gastric metaplasia, which is often colonised by Helicobacter pylori (H pylori), are increasingly recognised for their importance in the pathogenesis of duodenal ulcers. The situation is not clear in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs), who have a higher risk of peptic ulceration. The aim of this study was to identify the duodenal histological abnormalities in the presence or absence of NSAIDs, H pylon, and duodenal ulceration. Endoscopic duodenal biopsy specimens were taken from healthy looking mucosa of 172 patients (74 took NSAIDs, and 98 did not). Duodenitis was graded according to the degree of neutrophilic and plasma cell infiltration, villus height, Brunner's gland prolapse, and gastric metaplasia. The activity of duodenitis was dependent on the neutrophilic infiltration. A global score covering all the above factors was constructed, and H pylon in both the stomach and duodenum, was also assessed. The results showed that duodenitis with varying degrees of neutrophilic infiltration and gastric metaplasia was found in 20 patients (27%) taking NSAIDs, compared with 56 patients (57%) not taking NSAIDs (X2=l6 24, p<0-001). This degree of duodenitis was also found in 20 of 25 patients (80%) with duodenal ulcers, regardless of NSAID intake (X2=15-38, p<0.001). Gastric metaplasia was identified in 20 patients (27%) receiving NSAIDs and 38 (39%) not receiving NSAIDs. Duodenal H pylori was only seen in patients with gastric metaplasia 10 (50%) receiving NSAIDs, and 34 (89%) not receiving NSAIDs. H pylori positive gastritis, and the combination of active duodenitis and gastric metaplasia were independent predictors of duodenal ulceration. It is concluded that active duodenitis is less common in patients taking NSAIDs, but is strongly associated with gastric metaplasia, H pylori positive gastritis, and duodenal ulceration. These findings are relevant to the pathogenesis and treatment of duodenal ulcers in patients taking NSAIDs. (Gut 1993; 34: 1162-1166 Gastritis and duodenitis have, for a long time, been thought to play a part in the pathogenesis of peptic ulcer disease, and this concept has been further consolidated by the recognition of Helicobacter pylon (H pylon).' 2 Subsequently, it has been suggested that gastric metaplasia in the duodenum and H pylori associated gastritis might be synergistic in the pathogenesis of duodenitis, with the metaplastic gastric epithelium allowing H pylori to colonise the duodenal mucosa, where it produces an acute inflammatory response.3 Most studies in this field have been carried out in patients not taking nonsteroidal anti-inflammatory drugs (NSAIDs), and the role of duodenitis and gastric metaplasia in mediating NSAID related damage has, therefore, remained unclear.
ties in the presence or absence of NSAIDs, H pylon, and duodenal ulceration. Endoscopic duodenal biopsy specimens were taken from healthy looking mucosa of 172 patients (74 took NSAIDs, and 98 did not). Duodenitis was graded according to the degree of neutrophilic and plasma cell infiltration, villus height, Brunner's gland prolapse, and gastric metaplasia. The activity of duodenitis was dependent on the neutrophilic infiltration. A global score covering all the above factors was constructed, and H pylon in both the stomach and duodenum, was also assessed. The results showed that duodenitis with varying degrees of neutrophilic infiltration and gastric metaplasia was found in 20 patients (27%) taking NSAIDs, compared with 56 patients (57%) not taking NSAIDs (X2=l6 24, p<0-001). This degree of duodenitis was also found in 20 of 25 patients (80%) with duodenal ulcers, regardless of NSAID intake (X2=15-38, p<0.001). Gastric metaplasia was identified in 20 patients (27%) receiving NSAIDs and 38 (39%) not receiving NSAIDs. Duodenal H pylori was only seen in patients with gastric metaplasia 10 (50%) receiving NSAIDs, and 34 (89%) not receiving NSAIDs. H pylori positive gastritis, and the combination of active duodenitis and gastric metaplasia were independent predictors of duodenal ulceration. It is concluded that active duodenitis is less common in patients taking NSAIDs, but is strongly associated with gastric metaplasia, H pylori positive gastritis, and duodenal ulceration. These findings are relevant to the pathogenesis and treatment of duodenal ulcers in patients taking NSAIDs. (Gut 1993; 34: 1162 -1166 Gastritis and duodenitis have, for a long time, been thought to play a part in the pathogenesis of peptic ulcer disease, and this concept has been further consolidated by the recognition of Helicobacter pylon (H pylon).' 2 Gastritis was classified according to the Sydney System, which also covers chemical and lymphocytic gastritis. 5 8 Statistical analyses included the X2 test, analysis of variance, multiple and logistic regression where appropriate. All specimens carried code numbers, and the endoscopist and pathologists were not aware of any treatment being received by patients. The histological scoring was performed by the two pathologists separately in order to assess reproducibility. structed: in the absence of neutrophils, patients scoring four or less were considered normal; those scoring five or more were considered to have chronic duodenitis, in the absence of neutrophils. Chronic active duodenitis was diagnosed when intramucosal neutrophils were seen in patients scoring four or more.
The presence or absence of H pylori in the duodenal mucosa was also assessed using cresyl violet stain, and by culture of single duodenal biopsy specimens. Detection of H pylori by either histology or culture was considered as indicative of active infection in the duodenum.
Gastric antral biopsy specimens were also taken to check for the presence of H pylori by histology ( 
Results
A total of 172 patients were studied: 74 were receiving NSAIDs, and 98 were not. Table I shows the demographic data of the patients. Table III shows the characteristics of patients with gastric metaplasia; although there were relatively fewer cases of metaplasia in patients taking NSAIDs, the differences were not statistically significant. Also, patients not treated with NSAIDs were more likely to have heavy neutrophilic and mononuclear cell infiltration. The two groups were almost identical, however, in the extent of metaplasia, the number of smokers, patients with gastric H pylon, and duodenal ulcers. Similar to patients with active chronic duodenitis, most of the patients with duodenal ulcers (16/25, 64%) were also found to have gastric metaplasia (x2= 14-00, p<0 001). Table IV shows the prevalence of active duodenitis and gastric metaplasia in the presence or absence of the various types of gastritis. Most cases were found in association with H pylori positive gastritis, regardless of NSAID intake, although H pylorn was less common in patients receiving NSAID. Active duodenitis was uncommon in patients with normal gastric histology: its prevalence varied between 20% (on NSAIDs) and 24% (not on NSAIDs). It is also worth noting that 24 of 25 duodenal ulcers (96%), found in all patients, were associated with active antral gastritis, and that gastric H pylori was identified in 23 of duodenal ulcer patients (92%). Logistic regression showed that gastric Hpyloni and the combination of active duodenitis and gastric metaplasia were independent predictors of duodenal ulceration. On the other hand, only 11 (nine on NSAIDs) of 16 gastric ulcers (69%) had H pyloni related gastritis; the remaining five gastric ulcers were found in association with chemical gastritis, which was found only in patients taking NSAIDs. Gastric metaplasia tended to occur less frequently in our patients receiving NSAIDs, but the differences did not reach statistical significance. This, together with its close association with active duodenitis, is in agreement with the findings of two other studies.9' High acidity of the duodenal contents has for a long time been found to be associated with gastric metaplasia, both in humans39 ' 1 'I and in laboratory animals.'3 Acute exposure to NSAIDs is also known to stimulate gastric acid secretion,''7 which, at least in theory, should increase the prevalence of apply to gastric ulcers, eight of which (8/14, 57%) were positive for H pylorn.8
The relative rarity of active duodenitis in the NSAID group might explain, at least in part, why duodenal ulcers occur less commonly than gastric ulcers in such patients.2' 22 On the other hand, duodenal ulcers were still seen in comparable proportions in the presence or absence of NSAIDs, which could be because of other mechanisms of NSAID toxicity such as suppression of mucosal prostaglandins.
The prevalence of gastric H pylori, active duodenitis, and gastric metaplasia was similar in patients taking the various NSAIDs with the exception of diclofenac and ketoprofen. The prevalence of such findings tended to be lower in patients treated with gold injections than in those receiving sulphasalazine and NSAIDs.24 A firm statement could not, however, be made because ofthe relatively small numbers of patients taking the individual NSAID with or without second line drugs in this study.
In conclusion, despite the relative lack of active duodenitis in NSAID patients, a strong association exists between duodenal ulcers, active duodenitis, gastric metaplasia, and H pylori positive gastritis regardless of NSAID intake. This might be relevant to the understanding ofthe pathogenesis and the treatment of duodenal ulcers in chronic NSAID users. The potential benefits of eradicating H pylori in such patients are, however, still speculative, and their value remains to be proved.
